Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Reducing Mortality Among Older Adults: A Real-World Retrospective Cohort Study in Guangzhou, China

Why clinicians should know about it

• Picked for Pulmonary and Respiratory Medicine (paper of the day, 1 November 2026): Real-world pneumococcal vaccination outcomes include COPD mortality

Abstract

Objectives: To evaluate the real-world effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in reducing all-cause, pneumonia-related, and chronic obstructive pulmonary disease (COPD)-related mortality in adults aged ≥60 years. Methods: In this retrospective cohort study using existing health surveillance data, individuals aged ≥60 years on 1 January 2020 were followed until 31 August 2025 and classified by PPSV23 vaccination status. Propensity score matching (PSM) at a 1:1 ratio balanced sex, age, regional distribution, urbanization level and influenza vaccination status. Time-dependent Cox proportional hazards models estimated hazard ratios (HR) and vaccine effectiveness (VE), defined as (1 - HR) × 100%. Subgroup, negative control (mortality from traffic accidents), and E-value sensitivity analyses were performed. Results: After PSM, 453,500 individuals were included, with a mean follow-up of 5.61 years. All-cause mortality was 3.93 per 1000 person-years in vaccinated versus 9.57 in unvaccinated individuals. PPSV23 vaccination reduced all-cause mortality (VE = 43.1%, 95% CI: 41.2-45.0%), pneumonia-related mortality (VE = 46.2%, 95% CI: 39.6-52.1%), and COPD-related mortality (VE = 33.5%, 95% CI: 20.9-44.2%) (all p < 0.001). In a cause-specific decomposition, pneumonia- and COPD-related deaths together explained only 14.9% of the absolute reduction in all-cause deaths, whereas circulatory diseases and malignant tumors accounted for 36.8% and 31.9%, respectively. Among those also vaccinated against influenza, VE was 48.0% and 38.2% for pneumonia- and COPD-related mortality, respectively. For COPD-related mortality, the benefit was greater in men (VE = 42.3%) and in those aged ≥70 years (70-79 years, VE = 45.6%; ≥80 years, VE = 52.0%). PPSV23 was not associated with the negative control outcome (p = 0.247); E-values (1.98-2.44) indicated robustness to unmeasured confounding. Conclusions: PPSV23 vaccination was associated with significantly lower all-cause, pneumonia-related, and COPD-related mortality among elderly individuals aged ≥60 years. However, the observed association with all-cause mortality should be interpreted cautiously. Continued promotion of PPSV23 vaccination and advocacy for combined influenza-pneumococcal vaccination strategies are recommended.

Abstract as published, via PubMed.